李氏大藥廠(00950.HK)特許授權產品第III期臨牀試驗首名中國患者已入組
李氏大藥廠(00950.HK)公佈,全資附屬公司兆科藥業(合肥)的Intrarosa多中心、隨機、雙盲、並行組別第III期臨牀試驗的首名中國患者已經入組。Intrarosa爲Endoceutics,Inc.特許授權的產品,用於治療外陰陰道萎縮。
公司指,Intrarosa一直行銷於美國、加拿大及歐洲。目前於中國進行的第III期試驗旨在比較Intrarosa相對安慰劑對中國人羣的安全性與療效。預期入組完成時間爲2022年第三季。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.